Skip to content
Government Federal, Medical Health Aged Care

PHAA applauds passing of historic Tobacco Bill

Public Health Association of Australia 2 mins read

7 December 2023

The Public Health Association of Australia (PHAA) has congratulated the Australian Parliament on today passing the Public Health (Tobacco and Other Products) Bill 2023.

“The parliament’s action, which fulfils the Government’s historic update of national tobacco laws, represents one of the most important moments in Australia’s public health history,” Public Health Association of Australia (PHAA) CEO, Adj Prof Terry Slevin, said.

The Bill consolidates all of Australia’s current tobacco measures into a single Act and adds a suite of new protection measures including tackling digital advertising.

“This new legislation, coupled with vaping regulations which take effect from 1 January 2024, will save tens of thousands of lives, and reassert the country as a world-leader in tobacco control,” Adj Prof Slevin said.

“Congratulations and thank you to Health Minister Mark Butler for leading this important reform, and to the members of parliament and senators for their support. We also congratulate the public health experts and the broader public health community for their tireless advocacy over many years that has culminated in this legislation.

“Today is a very good day for the health of people in Australia. Perhaps more importantly it is excellent news for children in Australia, and future generations, who will be better protected against the influences of the tobacco industry. 

“We can never forget that their products have killed hundreds of millions of people around the world. All of these deaths have been preventable.”

 

Available for interview:

Prof Emily Banks AM, Professor of Epidemiology and Public Health, Head of the Centre for Public Health Data and Policy at the National Centre for Epidemiology and Population Health, The Australian National University

Dr Raglan Maddox, Convenor, PHAA Alcohol Tobacco and Other Drugs Special Interest Group, and Study Director of the Tackling Indigenous Smoking Evaluation, National Centre for Epidemiology and Public Health, ANU

 

For further information/comment:

Paris Lord (he/him), PHAA Communications & Media Manager, 0478 587 917, [email protected]  


Contact details:

For further information/comment:

Paris Lord (he/him), PHAA Communications & Media Manager, 0478 587 917, [email protected]  

Media

More from this category

  • Government Federal, Mental Health
  • 17/12/2025
  • 17:05
Australians for Mental Health

Australians for Mental Health welcomes mental health spend in mid-year budget update

Australians for Mental Health welcomes mental health spend in mid-year budget update Australians for Mental Health has welcomed the federal government’s decision to fund its election commitment of more than $1 billion for mental health care. The Mid-Year Economic and Fiscal Outlook released today confirms the mental health funding boosts, which will expand services and provide a boost to the workforce. The funding includes $500 million spent on a new network for 20 Youth Specialist Care Centres, $267.3 million for 32 new and upgraded Medicare Mental Health Centres, $225.3 million for 58 new, upgraded or expanded Headspace services and $83.9…

  • Medical Health Aged Care
  • 17/12/2025
  • 13:11
GE HealthCare

GE HealthCare and Indonesia’s Ministry of Health to expand access to quality care through the provision of 300+ advanced CT scanners

300+ advanced CT scanners to be installed in public hospitals across 38 provinces by 2028, to support early diagnosis and treatment of non-communicable diseases.…

  • Contains:
  • Finance Investment, Medical Health Aged Care
  • 17/12/2025
  • 12:03
Jane Morgan Management

LTR Pharma surpasses 1,000 SPONTANĀ® prescriptions under TGA Special Access Scheme

Highlights More than 1,000 SPONTAN® prescriptions issued under the TGA Special Access Scheme Growing prescriber network with continued uptake in complex ED cases, including post-prostate cancer patients Real-world insights informing US commercial strategy ahead of ROXUS® launch in H1 CY2026 LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the Company”) is pleased to announce that more than 1,000 SPONTAN® prescriptions have now been issued in Australia under the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS Category B). SPONTAN is being prescribed for patients with unmet clinical needs, including men who have not achieved adequate benefit from traditional oral PDE5 inhibitor…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.